Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677859 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
A Phase 1 study of Hematologic Malignancies, sponsored by Healios K.K..
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT00677859 is a Phase 1 study of Hematologic Malignancies that has completed, run by Healios K.K.. The registered enrollment target is 36 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00677859, a Phase 1 study of Hematologic Malignancies, has completed, sponsored by Healios K.K..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
Conditions Studied
Interventions
- BIOLOGICAL MultiStem®
Study Locations (6)
Arizona
- Mayo Clinic Hospital - Phoenix
Ohio
- University Hospitals Case Medical Center - Cleveland
Oregon
- Oregon State University Medical Center - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Texas Transplant Institute - San Antonio
Other
- UZ Leuven - Leuven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677859
The ClinicalTrials.gov registry entry for NCT00677859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The listed sponsor is Healios K.K., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MultiStem® is the first listed.
NCT00677859 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT00677859 about?
NCT00677859 is a clinical study titled "Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia". The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
What is the current status of trial NCT00677859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-07. Estimated completion is 2011-11.
What conditions does trial NCT00677859 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT00677859?
The interventions under investigation include: MultiStem® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00677859?
This trial is sponsored by Healios K.K., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677859 being conducted?
This trial has 6 study locations across Arizona, Ohio, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.